They will find a new biomarxer from Parkinson’s disease in body fluids

Researchers at the University of Protein Diagnosis (Germany) And invented from Betanese Biotechnology Easy the reliable diagnosis in the early stages of a biomarker disease in the cerebrospinal fluid Parkinson And he can illuminate his progress and the effect of a treatment.

This is indicated in their inventions published in the ‘Molecular EMBO Medicine’ magazine. Parkinson’s disease is characterized by the loss of dopamineric nerve cells in the brain, This usually causes a growing motor decline as symptoms progress.

Dopamine supplements may compensate for loss and temporarily eliminates symptoms. Poor folding of Alpha-Sinuclein Key Protein (Asin) plays an important role in the development of Parkinson’s disease.

“This bad folding sticks to the protein, which leads to the formation of large campuses, calls Oligo -Bar. Oligomers create long fibrillaries, and these fibers are gathered in the brain of macroscopic large Louis bodies, ”explains the founder, Prodi Manager and CEO of Petasansens, Professor Class Gervard.

Of the two independent medical associates with a total of 134 participants, Poocha researchers showed that Asin this poor fold in body fluids, with more than 905 sensitivity and specification Finding Parkinson’s disease.

To help develop treatments

Carried out using the investigation Cerebrospinal liquid samples Patients from Parkinson’s centers in Pocham (St. Joseph Hospital) and Casal (Paracells-Elena-Cinic). The IRS patent technology (immunoinfrazo sensor) was made with measurements.

At this time, Petasnes assures it This has already been successfully used to be successful IRS technologylzheimer. In this case, the poor folding of biomarker A was shown to indicate the risk of Alzheimer’s dementia in a rear phase with great accuracy of up to 17 years. “Now we have moved this approach to Asin’s bad fold for Parkinson,” says Class Gervard.

In addition to diagnostic applications, technology also claims researchers say To help create new active items And prove its performance in clinical trials.